ATSN-201 Gene Therapy Shows Improvement in XLRS at 18 Months

Clinical Report: ATSN-201 Gene Therapy Shows Improvement in XLRS at 18 Months

Overview

The LIGHTHOUSE trial demonstrated that ATSN-201, an investigational gene therapy for X-linked retinoschisis (XLRS), resulted in sustained structural and functional improvements at 18 months. Notably, foveal schisis closure was maintained in 7 of 9 treated eyes, with significant visual acuity gains observed.

Background

X-linked retinoschisis (XLRS) is a genetic disorder characterized by macular schisis and vision impairment due to mutations in the RS1 gene. Current treatment options are limited, focusing primarily on supportive care. The development of gene therapies like ATSN-201 represents a potential advancement in the management of this condition.

Data Highlights

Outcome	Treated Eyes	Untreated Eyes
Foveal schisis closure	7 of 9	0
Improvement of at least 7 dB on microperimetry	6	0
Gains of at least 10 letters in visual acuity	7	1

Key Findings

ATSN-201 showed sustained foveal schisis closure in 7 of 9 treated eyes at 18 months.
Six treated eyes demonstrated an improvement of at least 7 dB on microperimetry.
Seven treated eyes achieved gains of at least 10 letters in visual acuity compared to only 1 untreated eye.
No drug-related serious adverse events or dose-limiting toxicities were reported.
The trial is ongoing, with enrollment expected to conclude in early 2027.

Clinical Implications

Continued monitoring of safety and efficacy in the ongoing trial will be essential.

Conclusion

The 18-month results from the LIGHTHOUSE trial indicate outcomes for ATSN-201 in treating XLRS.